These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 32517194)

  • 21. New agents for endocrine resistance in breast cancer.
    Maurer C; Martel S; Zardavas D; Ignatiadis M
    Breast; 2017 Aug; 34():1-11. PubMed ID: 28448864
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma.
    Bièche I; Girault I; Urbain E; Tozlu S; Lidereau R
    Breast Cancer Res; 2004; 6(3):R252-63. PubMed ID: 15084249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Knockdown of ICB-1 gene enhanced estrogen responsiveness of ovarian and breast cancer cells.
    Konwisorz A; Springwald A; Haselberger M; Goerse R; Ortmann O; Treeck O
    Endocr Relat Cancer; 2010 Mar; 17(1):147-57. PubMed ID: 19942713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines.
    Sikora MJ; Jacobsen BM; Levine K; Chen J; Davidson NE; Lee AV; Alexander CM; Oesterreich S
    Breast Cancer Res; 2016 Sep; 18(1):92. PubMed ID: 27650553
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epigenetic mechanisms in breast cancer therapy and resistance.
    Garcia-Martinez L; Zhang Y; Nakata Y; Chan HL; Morey L
    Nat Commun; 2021 Mar; 12(1):1786. PubMed ID: 33741974
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Estrogen Receptor Cofactor SPEN Functions as a Tumor Suppressor and Candidate Biomarker of Drug Responsiveness in Hormone-Dependent Breast Cancers.
    Légaré S; Cavallone L; Mamo A; Chabot C; Sirois I; Magliocco A; Klimowicz A; Tonin PN; Buchanan M; Keilty D; Hassan S; Laperrière D; Mader S; Aleynikova O; Basik M
    Cancer Res; 2015 Oct; 75(20):4351-63. PubMed ID: 26297734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endocrine therapy resistance in estrogen receptor (ER)-positive breast cancer.
    De Marchi T; Foekens JA; Umar A; Martens JW
    Drug Discov Today; 2016 Jul; 21(7):1181-8. PubMed ID: 27233379
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endocrine treatment in breast cancer: Cure, resistance and beyond.
    Tryfonidis K; Zardavas D; Katzenellenbogen BS; Piccart M
    Cancer Treat Rev; 2016 Nov; 50():68-81. PubMed ID: 27643748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An H3K4me3 reader, BAP18 as an adaptor of COMPASS-like core subunits co-activates ERα action and associates with the sensitivity of antiestrogen in breast cancer.
    Sun G; Wang C; Wang S; Sun H; Zeng K; Zou R; Lin L; Liu W; Sun N; Song H; Liu W; Zhou T; Jin F; Shan Z; Zhao Y
    Nucleic Acids Res; 2020 Nov; 48(19):10768-10784. PubMed ID: 32986841
    [TBL] [Abstract][Full Text] [Related]  

  • 30. USP9X downregulation renders breast cancer cells resistant to tamoxifen.
    Oosterkamp HM; Hijmans EM; Brummelkamp TR; Canisius S; Wessels LF; Zwart W; Bernards R
    Cancer Res; 2014 Jul; 74(14):3810-20. PubMed ID: 25028367
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients.
    Gao Q; López-Knowles E; Cheang MCU; Morden J; Ribas R; Sidhu K; Evans D; Martins V; Dodson A; Skene A; Holcombe C; Mallon E; Evans A; Bliss JM; Robertson J; Smith I; Martin LA; Dowsett M;
    Breast Cancer Res; 2019 Dec; 22(1):2. PubMed ID: 31892336
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer.
    Alves CL; Elias D; Lyng MB; Bak M; Ditzel HJ
    Breast Cancer Res; 2018 Jun; 20(1):60. PubMed ID: 29921289
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Closer Look at Estrogen Receptor Mutations in Breast Cancer and Their Implications for Estrogen and Antiestrogen Responses.
    Clusan L; Le Goff P; Flouriot G; Pakdel F
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33451133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extended adjuvant chemotherapy in endocrine non-responsive disease.
    Colleoni M; Munzone E
    Breast; 2013 Aug; 22 Suppl 2():S161-4. PubMed ID: 24074780
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer.
    Colleoni M; Munzone E
    Drugs; 2015 Aug; 75(12):1311-21. PubMed ID: 26177891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endocrine resistance in breast cancer: from cellular signaling pathways to epigenetic mechanisms.
    Bianco S; Gévry N
    Transcription; 2012; 3(4):165-70. PubMed ID: 22771991
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Understanding response and resistance to oestrogen deprivation in ER-positive breast cancer.
    Patani N; Martin LA
    Mol Cell Endocrinol; 2014 Jan; 382(1):683-694. PubMed ID: 24121024
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estrogen Receptor Bio-Activities Determine Clinical Endocrine Treatment Options in Estrogen Receptor-Positive Breast Cancer.
    Xia S; Lin Q
    Technol Cancer Res Treat; 2022; 21():15330338221090351. PubMed ID: 35450488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
    Jerusalem G; Bachelot T; Barrios C; Neven P; Di Leo A; Janni W; de Boer R
    Cancer Treat Rev; 2015 Feb; 41(2):94-104. PubMed ID: 25575443
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Biomarkers of endocrine therapy-resistance in breast cancers].
    de Cremoux P; Debled M; Bonnefoi H; Cottu P
    Bull Cancer; 2010 Aug; 97(8):951-63. PubMed ID: 20605764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.